EGFR and endometrial cancer: GSEA revealed the top five active pathways in the high-risk group including cell cycle, endometrial cancer, ERBB signaling pathway, TGF-β signaling pathway, and WNT signaling pathway (Figure 7A), while the low-risk group included allograft rejection, autoimmune thyroid disease, graft versus host disease, intestinal immune network for IgA production, and primary immunodeficiency (Figure 7B).